Moran, A., Polesso, F., & Weinberg, A. (2014). OX40 agonist immunotherapy expands tumor reactive CD8 T cells with a unique T cell receptor repertoire and synergizes with PDL-1 blockade to promote tumor regression. J Immunother Cancer.
Chicago Style CitationMoran, Amy, Fanny Polesso, and Andrew Weinberg. "OX40 Agonist Immunotherapy Expands Tumor Reactive CD8 T Cells With a Unique T Cell Receptor Repertoire and Synergizes With PDL-1 Blockade to Promote Tumor Regression." J Immunother Cancer 2014.
MLA CitationMoran, Amy, Fanny Polesso, and Andrew Weinberg. "OX40 Agonist Immunotherapy Expands Tumor Reactive CD8 T Cells With a Unique T Cell Receptor Repertoire and Synergizes With PDL-1 Blockade to Promote Tumor Regression." J Immunother Cancer 2014.